Comprehensive assessment of using micronised purified flavonoid fraction in the correction of disorders associated with ADMA-like preeclampsia in experiment
Background: About 10% of pregnancies in the world are accompanied by hypertensive disorders, while from 2 to 8% are preeclampsia. One of the components of the pathogenesis of preeclampsia is placental ischemia. The humoral factors released during preeclampsia have a pro-inflammatory effect and can contribute to the development of endothelial dysfunction. One of the possible options for reducing the effects of these cytokines may be the use of drugs containing natural flavonoids, one of the positive aspects of which is the reduction of venospecific inflammation. The aim of the study: To study the effectiveness of using purified micronized flavonoid fraction (diosmin+flavonoids expressed as hesperidin) in the correction of functional disorders that occur during preeclampsia in the experiment. Materials and methods: The experiment was performed on 100 white female rats of the Wistar line weighing 250-300 g. ADMA-like agent (L-NAME) was introduced intraperitoneally at a dose of 25 mg/kg/day from 14 to 20 days of gestation. The purified micronized flavonoid fraction (diosmin + flavonoids expressed as hesperidin) in dosages of 86 mg/kg and 260 mg/kg was administered orally once a day from 14 to 20 days of pregnancy. On the 21st day of pregnancy, functional tests and laboratory tests were performed. Results: The administration of purified micronized flavonoid fraction to laboratory animals leads to a pronounced correction of pathological changes in experimental ADMA-like preeclampsia with the greatest effect in a higher dose of the drug used. A significant decrease in systolic and diastolic pressure was noted, respectively, improved microcirculation in the placenta, restoration of the NO-synthesizing function of the endothelium, and a decrease in proteinuria. Conclusion: The results of the study indicate the promise of using a purified micronized flavonoid fraction for the correction of functional changes in preeclampsia and substantiate the feasibility of further research in this direction.